Search
Menu
Home
HTB
2019
August
August 2019
Contents
Editorial
HTB 23 August 2019 online: second reports from IAS 2019
Special reports
Fit for purpose: antiretroviral treatment optimisation July 2019
Conference reports
10th IAS Conference on HIV Science (IAS 2019) in Mexico City
Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution
Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance
Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
Dolutegravir for younger children: results from the ODYSSEY trial
PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study
Antiretrovirals
Cabotegravir/rilpivirine long-acting injectable HIV drugs submitted to EMA
PDFs
23 August 2019 vol 20 no 10
HTB RSS
Early access
Viral failure on CAB/RPV-LA: overcoming drug resistance with second-generation INSTIs
13 April 2025
Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care
3 April 2025
All early access reports
Current issues
April 2025
March 2025
February 2025
Back issues
Special report
Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care
3 April 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate